HANSHOW
30.5.2022 09:02:12 CEST | Business Wire | Press release
European retailers are some of the world’s earliest adopters of electronic shelf labels (ESLs) to reduce operations costs as a foundation for retail digitalization. Now at this week’s EuroCIS 2022 trade show, the new IoT platform All-Star is being released and introduced by the digital solutions provider Hanshow (EuroCIS booth - 9 D13), poised to drive Europe’s brick‐and‐mortar retail into a new era of efficiency and profitability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005588/en/
Entering the European market in 2016, Hanshow has been a major driver of this transformation with now nearly 100 million ESLs installed on the continent. This time at EuroCIS 2022, Hanshow is displaying a range of new solutions from AI-powered shelf monitoring to self-checkout trolleys and in-store marketing, constantly shaping smart stores of the future.
Chief among the new technologies presented by Hanshow at EuroCIS is the IoT platform All-Star, focusing on the retail industry and designed specifically to help retailers to expand and upgrade their digitalization. All-Star provides one-stop IoT solutions from IoT device management to digital operations upgrades, empowering retail customers to quickly establish IoT equipment management capabilities and be able to flexibly build business applications and integrate customized business connections to further boost operation efficiency of smart stores and elevate in-store experience of the customers, ranging over key functions of pricing management, inventory management, picking, geolocation, dynamic pricing, promotion boards, interactive marketing, digital payment, passenger flow analysis and automatic monitoring patrol.
The All‐Star platform thus works as an integrated system for the management of a store’s entire digital devices, providing SaaS and private deployment solutions, both of which support unified user authentication and third-party application access integration with an open API based on HTTP. Correspondingly, one of its key product innovations is to solve the new challenges arising with the amount of IoT devices all operating on different networks and communicating on different transmission signals, as one store may require a handful of login systems with operations personnel trained in each. Therefore, each retail solution management platform may now be accessed through All-Star for a holistic integration of all the core business operation processes, significantly simplifying the maintenance of these devices.
In tandem with the All-Star system, Hanshow has also developed an industry-first communications protocol that uses one transmission frequency to communicate with all Hanshow IoT devices, easing the burden on the range of signal frequencies previously needed.
“Hanshow has developed All-Star and the rest of its solutions specifically with global retailers in mind to achieve a more holistic form of digitalization. These new solutions, software, and transmission technologies all combine to help retailers in Europe move into an exciting new era of digitalization,” said Shiguo Hou. “This unlocks great new opportunities. We’re just seeing the beginning of what’s possible.”
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. Hanshow is dedicated to offering its global customers a series of world‐class customized IoT touchpoints and digital store solutions that deliver customer‐centric insights, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Hanshow currently serves over 30,000 stores in more than 50 countries. Learn more: www.hanshow.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005588/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
